Adrenaline of epinephrine can be seen in autonomic neuropathy or following adrenalectomy. Failure of the adrenal cortex, as with Addisons disease, can suppress epinephrine secretion as the activity of the synthesing enzyme, phenylethanolamine-"N"-methyltransferase, depends on the high concentration of cortisol that drains from the cortex to the medulla. In 1901, Jokichi Takamine patented a purified extract from the adrenal glands, and called it "adrenalin" (from the Latin for "on top of the kidneys" ("ad" and "renal"), which was trademarked by Parke, Davis & Co in the US. The British Approved Name and European Pharmacopoeia term for this drug is hence "adrenaline".
Pure autonomic failure primary dysautonomia), including Pure Autonomic Failure, Multiple System Atrophy, and Parkinson's. The primary differentiating characteristic of Pure autonomic failure is decreased circulation and synthesis of norepinephrine, and dysfunction localized peripherally. It is relevant to note that progression to central nervous system neurodegeneration can also occur. It is named for Samuel Bradbury and Cary Eggleston. Pure autonomic failure Pure autonomic failure (PAF) is a form of dysautonomia that first occurs in middle age or later in life; men are affected more often than women. A degenerative disease of the autonomic nervous system, symptoms include dizziness and fainting (caused by orthostatic hypotension),